Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus capecitabine and cisplatin in tissue HER2-negative but serum HER2-positive advanced gastric cancer
KCT0004391Phase 2Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Daewoong Pharmaceutical. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on KCT0004391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004391.